文献速递冠心病外科

SYNTAX试验十年生存获益:外科与经皮血运重建的适宜比例

Ten-year survival benefit and appropriateness of surgical versus percutaneous revascularization in synergy between percutaneous coronary intervention with Taxus and cardiac surgery randomized trial.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

该研究基于SYNTAX随机试验1800例患者及1275例注册队列患者,使用SYNTAX评分II-2020评估十年全因死亡预测与观察比值。结果显示,在全部SYNTAX试验人群中,预测从冠状动脉旁路移植术(CABG)获得生存获益的比例为82.4%(2143/2602),经皮冠状动脉介入治疗(PCI)为17.7%(459/2602),对应CABG与PCI适宜治疗分配比为4.7比1。结论认为血运重建方式应基于个体长期预后而非平均治疗效应。

要点

  • SYNTAX评分II-2020可预测CABG注册队列十年死亡率,C指数0.70。
  • 全部试验人群中82.4%预测从CABG获益,17.7%从PCI获益。
  • CABG与PCI的适宜治疗分配比为4.7比1。

核心结论

  • 血运重建方式选择应取决于个体长期预后而非平均治疗效应。
  • 应告知患者其预测预后。

研究设计与样本

  • 研究纳入1800例随机患者和1275例嵌套注册患者(PCI注册198例,CABG注册1077例)。
  • 主要终点为十年全因死亡率。
  • SYNTAX评分II-2020在随机队列内外部验证,并在注册队列外部验证。

主要发现

  • 随机队列十年死亡率:CABG为23.8%,PCI为28.6%。
  • 注册队列十年死亡率:CABG为27.6%,PCI为55.4%。
  • CABG注册队列中SYNTAX评分II-2020预测十年死亡率校准良好(C指数0.70,截距0.00,斜率0.76)。
  • 全部SYNTAX试验人群中预测从CABG获得生存获益比例为82.4%(2143/2602),PCI为17.7%(459/2602)。
  • CABG与PCI的适宜治疗分配比为4.7比1。

关键数值与推荐

  • SYNTAX评分II-2020用于确定CABG或PCI生存获益的适宜患者比例。
  • CABG注册队列中SYNTAX评分II-2020的C指数为0.70,截距0.00,斜率0.76。

临床怎么用

  • 临床决策应基于个体化长期预后评估而非平均治疗效应。
  • 可使用SYNTAX评分II-2020预测患者十年死亡风险以指导血运重建方式选择。
  • 应与患者沟通其预测预后以辅助共同决策。

局限性

  • 研究基于SYNTAX试验人群,结论外推需谨慎。
  • 注册队列样本量及构成可能影响结果普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Average treatment effects from randomized trials do not reflect the heterogeneity of an individual's response to treatment. This study evaluates the appropriate proportions of patients for coronary artery bypass grafting, or percutaneous intervention based on the predicted/observed ratio of 10-year all-cause mortality in the SYNTAX population. METHODS: The study included 1800 randomized patients and 1275 patients in the nested percutaneous (n = 198) or surgical (n = 1077) registries. The primary end point was 10-year all-cause mortality. The SYNTAX score II-2020 was validated internally in the randomized cohort and externally in the registry cohort. Proportions of patients with survival benefits from coronary artery bypass grafting or percutaneous intervention were determined using SYNTAX score II-2020. RESULTS: Ten-year mortality was 23.8% for coronary artery bypass grafting, 28.6% for percutaneous intervention in the randomized cohort, 27.6% for coronary artery bypass grafting and 55.4% for percutaneous intervention in the registries. In the coronary artery bypass grafting registry, the SYNTAX score II-2020 predicted 10-year mortality with helpful calibration and discrimination (C-index: 0.70, intercept: 0.00, slope: 0.76). The proportion of patients deriving a predicted survival benefit from coronary artery bypass grafting over percutaneous intervention was 82.4% (2143/2602) and 17.7% (459/2602) for the entire SYNTAX trial population, translating into a 4.7 to 1 appropriate ratio of treatment allocation to coronary artery bypass grafting and percutaneous intervention. CONCLUSIONS: Choosing a revascularization modality should depend on an individual's long-term prognosis rather than average treatment effects. Additionally, patients should be informed about their predicted prognosis. TRIAL REGISTRATION: Registered on clinicaltrial.gov. SYNTAXES: NCT03417050 (https://clinicaltrials.gov/ct2/show/NCT03417050). SYNTAX: NCT00114972 (https://www.clinicaltrials.gov/ct2/show/NCT00114972).

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Serruys PW, Ninomiya K, Revaiah PC, et al. Ten-year survival benefit and appropriateness of surgical versus percutaneous revascularization in synergy between percutaneous coronary intervention with Taxus and cardiac surgery randomized trial. Eur J Cardiothorac Surg. 2024. PMID: 39447048. doi:10.1093/ejcts/ezae391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。